(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number
WO 2003/102190 A3

(51) International Patent Classification[7]: C12N 15/31, C07K 14/195, C12N 15/62, G01N 33/50

(21) International Application Number: PCT/CA2003/000786

(22) International Filing Date: 2 June 2003 (02.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/384,634	31 May 2002 (31.05.2002)	US
60/385,157	31 May 2002 (31.05.2002)	US
60/385,611	4 June 2002 (04.06.2002)	US
60/385,747	4 June 2002 (04.06.2002)	US
60/385,752	4 June 2002 (04.06.2002)	US
60/385,780	4 June 2002 (04.06.2002)	US
60/385,797	4 June 2002 (04.06.2002)	US
60/385,785	4 June 2002 (04.06.2002)	US
60/385,542	4 June 2002 (04.06.2002)	US
60/385,773	4 June 2002 (04.06.2002)	US
60/385,750	4 June 2002 (04.06.2002)	US
60/386,350	5 June 2002 (05.06.2002)	US
60/385,962	5 June 2002 (05.06.2002)	US
60/386,141	5 June 2002 (05.06.2002)	US
60/386,586	5 June 2002 (05.06.2002)	US
60/386,024	5 June 2002 (05.06.2002)	US
60/386,022	5 June 2002 (05.06.2002)	US
60/386,087	5 June 2002 (05.06.2002)	US
60/386,834	6 June 2002 (06.06.2002)	US
60/386,368	6 June 2002 (06.06.2002)	US
60/386,441	6 June 2002 (06.06.2002)	US
60/386,528	6 June 2002 (06.06.2002)	US
60/386,369	6 June 2002 (06.06.2002)	US
60/386,436	6 June 2002 (06.06.2002)	US
60/386,573	6 June 2002 (06.06.2002)	US
60/399,861	31 July 2002 (31.07.2002)	US
60/399,984	31 July 2002 (31.07.2002)	US
60/399,983	31 July 2002 (31.07.2002)	US
60/399,969	31 July 2002 (31.07.2002)	US
60/399,985	31 July 2002 (31.07.2002)	US
60/399,970	31 July 2002 (31.07.2002)	US
60/399,839	31 July 2002 (31.07.2002)	US
60/400,363	1 August 2002 (01.08.2002)	US
60/400,436	1 August 2002 (01.08.2002)	US
60/400,268	1 August 2002 (01.08.2002)	US
60/400,442	1 August 2002 (01.08.2002)	US
60/400,154	1 August 2002 (01.08.2002)	US
60/400,463	1 August 2002 (01.08.2002)	US
60/400,434	1 August 2002 (01.08.2002)	US

[Continued on next page]

(54) Title: BACTERIAL POLYPEPTIDES INVOLVED IN VIABILITY



Measured Mass(M)	Avg/ Mono	Computed Mass	Error (Da)	Residues Start	To	Missed Cut	Peptide sequence
935.464	M	935.580	-0.116	250	257	0	IAIELHLK
983.521	M	983.612	-0 091	258	266	1	RLIVGGLEK
1091.576	M	1091.681	-0.105	250	258	1	IAIELHLKR
1163.501	M	1163.604	-0.103	273	282	1	VFRNEGVSTR
1175.533	M	1175.629	-0.096	449	458	1	GRFEAQLVEK
1241.512	M	1241.615	-0.103	169	178	0	FHGLQDIEQR
1256.474	M	1256.592	-0.118	347	357	0	EATGVDFYEVK
1343.679	M	1343.748	-0 069	493	504	0	LVMLLTDSPSIR
1438.625	M	1438.693	-0.068	183	194	0	YLDLITNEDSTR
1498.724	M	1498.793	-0.069	421	432	1	FTDRFELFIVGR
1523.651	M	1523.740	-0.090	379	390	0	YGHILNEFFEQK
1580.655	M	1580.699	-0.044	20	32	0	VMSEEMNDQMLVR
1593.680	M	1593.730	-0.051	114	126	1	KDQVGDDEFDLWK
1662.779	M	1662 828	-0.049	127	142	0	NADLGDIVGVEGVMFK
1722.803	M	1722.853	-0.050	181	194	1	QRYLDLITNEDSTR
2582.301	M	2582 362	-0.061	391	413	0	VEETLIQPTFIYGHPTEISPLAK

(57) Abstract: The present invention relates to polypeptide targets for pathogenic bacteria. The invention also provides biochemical and biophysical characteristics of those polypeptides.

WO 2003/102190 A3

60/400,433	1 August 2002 (01.08.2002)	US
60/400,374	1 August 2002 (01.08.2002)	US
60/400,365	1 August 2002 (01.08.2002)	US
60/400,380	1 August 2002 (01.08.2002)	US
60/400,230	1 August 2002 (01.08.2002)	US

(71) **Applicant** *(for all designated States except US)*: **AFFINIUM PHARMACEUTICALS, INC.** [CA/CA]; 100 University Avenue, 10th Floor, South Tower, Toronto, Ontario M5J 1V6 (CA).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **EDWARDS, Aled** [CA/CA]; 21 Sutherland Drive, Toronto, Ontario M4G 1H1 (CA). **DHARAMSI, Akil** [CA/CA]; 29 Moresby Street, Richmond Hill, Ontario L4B 4K9 (CA). **VEDADI, Masoud** [CA/CA]; 178 Northwood Drive, Toronto, Ontario M2M 2K3 (CA). **VALLEE, Francois** [FR/CA]; 490 Eglinton Avenue East, Apt. 405, Toronto, Ontario M4P 1M4 (CA). **AWREY, Donald** [CA/CA]; 2211 Stir Crescent, Mississauga, Ontario L4Y 3V2 (CA). **BEATTIE, Bryan** [CA/CA]; 2224 Vista Oak Road, Oakville, Ontario L6M 3L7 (CA). **RICHARDS, Dawn** [CA/CA]; 45 Balliol Street, #1414, Toronto, Ontario M4S 1C3 (CA). **DOMAGALA, Megan** [CA/CA]; #135-815 Hillcrest Ave., Mississauga, Ontario L5B 4B1 (CA). **MANSOURY, Kamran** [CA/CA]; 44 Gerard Street, #1408, Toronto, Ontario M5G 2K2 (CA). **VIRAG, Cristina** [CA/CA]; 26 Geraldine Court, Brampton, Ontario L6S 2J6 (CA). **BUZADZIJA, Kristina** [CA/CA]; 880 Dundas Street West, Apt. 1102, Mississauga, Ontario L5C 4H3 (CA). **MCDONALD, Merry-Lynn** [CA/CA]; 24 Sayor Drive, Ajax, Ontario P3E 1R7 (CA). **HOUSTON, Simon** [GB/CA]; 100 Vaughan Road, Apt. 29, Toronto, Ontario M6C 2M1 (CA). **ARROWSMITH, Cheryl** [US/CA]; 25 Orchid Court, Toronto, Ontario M2L 2X8 (CA). **OUYANG, Hui** [CA/CA]; 6 Esterbrooke Ave., Unit 76, North York, Ontario M2J 2C2 (CA). **NETHERY, Kathleen** [CA/CA]; 1185 Lansdowne Avenue, Lower Unit, Toronto, Ontario M6H 3Z7 (CA). **NG, Ivy** [CA/CA]; 33 Isabella Street, Suite 2115, Toronto, Ontario M4Y 2P7 (CA). **KANAGARAJAH, Dhushy** [CA/CA]; #1402-4450 Tucana Court, Mississauga, Ontario L5R 3R4 (CA).

(74) **Agent: BERESKIN & PARR**; 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2 (CA).

(81) **Designated States** *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) **Date of publication of the international search report:** 21 May 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
P[redacted]CA 03/00786

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/31 C07K14/195 C12N15/62 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, Sequence Search, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL, HEIDELBERG, FRG [Online] SEQ ID NO: 4215 of WO0170955 13 February 2002 (2002-02-13), "Staphylococcus aureus DNA for cellular proliferation protein #50" XP002265525 Database accession no. AAS51633 the whole document -/--	1,45-67

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 December 2003	31 03 2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Fuchs, U

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	-& WO 01/070955 A (ELITRA PHARMACEUTICALS, INC.) 27 September 2001 (2001-09-27) abstract page 2, line 1 - page 5, line 3 SEQ ID NO: 4215 page 64, line 5 - page 86, line 7 page 125 - page 134; example 11A locus ID NO: SAU100414 SEQ ID NO: 12148 page 161; table VIIA PathoSeq Cluster ID NO: 362 page 228; table VIIB page 243, line 36 - page 249, line 33 page 276; table VIII SEQ ID NO: 1723 page 332; table IA SEQ ID NO: 2387 page 345; table IA SEQ ID NO: 5270 page 416; table IA page 432; table IA page 476; table IA page 490 - page 504; claims 1-44	1,45-67

X	DATABASE EMBL, HEIDELBERG, FRG [Online] SEQ ID NO: 5270 of WO0170955 14 February 2002 (2002-02-14), "Staphylococcus aureus cellular proliferation protein #50" XP002265526 Database accession no. AAU33774 the whole document	1,45-67
X	& WO 01/070955 A (ELITRA PHARMACEUTICALS, INC.) 27 September 2001 (2001-09-27) SEQ ID NO: 5270	1,45-67

X	DATABASE EMBL, HEIDELBERG, FRG [Online] SEQ ID NO: 1723 of WO0170955 13 February 2002 (2002-02-13), "Staphylococcus aureus cellular proliferation inhibitory sequence #370" XP002265527 Database accession no. AAS49146 the whole document	1,45-67
X	& WO 01/070955 A (ELITRA PHARMACEUTICALS, INC.) 27 September 2001 (2001-09-27) SEQ ID NO: 1723	1,45-67

	-/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL, HEIDELBERG, FRG [Online] SEQ ID NO: 2387 of WO0170955 13 February 2002 (2002-02-13), "Staphylococcus aureus cellular proliferation inhibitory sequence #1034" XP002265528 Database accession no. AAS49810 the whole document	1,45-67
X	& WO 01/070955 A (ELITRA PHARMACEUTICALS, INC.) 27 September 2001 (2001-09-27) SEQ ID NO: 2387	1,45-67

L	DATABASE EMBL, HEIDELBERG, FRG [Online] SEQ ID NO: 2293 20 February 2003 (2003-02-20), XP002265529 Database accession no. AX619330 cited to provide information on the relevant sequence disclosed in WO02094868 the whole document	1,45-67
P,X	-& WO 02/094868 A (CHIRON SPA) 28 November 2002 (2002-11-28) abstract SEQ ID NOS: 2293 and 2294 page 1, line 17 - page 7, line 16 page 8, line 25 - page 20, line 34 page 35 - page 48; claims 1-22	1,45-67

L	DATABASE EMBL, HEIDELBERG, FRG [Online] SEQ ID NO: 2294 20 February 2003 (2003-02-20), XP002265530 Database accession no. AX619331 cited to provide information on the relevant sequence disclosed in WO02094868 the whole document	1,45-67
P,X	& WO 02/094868 A (CHIRON SPA) 28 November 2002 (2002-11-28) SEQ ID NO: 2294	1,45-67

A	DATABASE EMBL, HEIDELBERG, FRG [Online] 1 November 1997 (1997-11-01), GREEN, C.J. & VOLD, B.S.: "Lysyl-tRNA synthetase (EC 6.1.1.6) (Lysine--tRNA ligase) (LysRS)" XP002265531 Database accession no. Q53638 derived from S. aureus strain ATCC 12600 the whole document	1,45-67

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
P[redacted]/CA 03/00786

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 094 070 A (PFIZER PRODUCTS INC.) 25 April 2001 (2001-04-25) abstract lysS gene page 8, line 13 - line 57 page 12, line 33 - page 16, line 8 page 25, line 18 - line 26	1,45-67
A	BROWN, M.J.B. ET AL.: "Rational Design of Femtomolar Inhibitors of Isoleucyl tRNA Synthetase from a Binding Model for Pseudomonic Acid-A" BIOCHEMISTRY, vol. 39, no. 20, 23 May 2000 (2000-05-23), pages 6003-6011, XP002249801 the whole document	1,45-67
A	BAGBY, S. ET AL.: "Optimization of Protein Solubility and Stability for Protein Nuclear Magnetic Resonance" METHODS IN ENZYMOLOGY, vol. 339, 2001, pages 20-41, XP001152932 the whole document	1,45-67
A	KRAFT, P. ET AL.: "Infrared, Surface-Assisted Laser Desorption Ionization Mass Spectrometry on Frozen Aqueous Solutions of Proteins and Peptides Using Suspensions of Organic Solids" JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, vol. 9, no. 9, September 1998 (1998-09), pages 912-924, XP004149186 the whole document	1,45-67

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 03/00786

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 (completely), 45-67 (all partially)

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1 (completely), 45-67 (all partially)

A composition comprising an isolated, recombinant polypeptide wherein the polypeptide comprises: a) an amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 7, b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 7, or c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 4 or SEQ ID NO: 6 and has at least one biological activity of lysyl-tRNA synthetase from Staphylococcus aureus and wherein the polypeptide of a), b) or c) is at least about 90% pure in a sample of the composition, a host cell comprising a nucleic acid encoding a polypeptide comprising said composition wherein a culture of the host cell produces at least about 1 mg of said polypeptide per liter of culture and the polypeptide is at least about one-third soluble as measured by gel electrophoresis, said composition wherein at least two-thirds of the polypeptide in the sample is soluble, said composition, wherein the polypeptide is fused to at least one heterologous polypeptide that increases the solubility or stability of the polypeptide, said composition which further comprises a matrix suitable for mass spectrometry, said composition wherein the polypeptide of a), b) or c) is labeled with a heavy atom, said composition being a crystallized, recombinant polypeptide wherein the polypeptide of a), b) or c) is in crystal form, a method for designing a modulator for the prevention or treatment of a disease or disorder associated with S. aureus involving a three-dimensional structure for said crystallized, recombinant polypeptide, said composition wherein the polypeptide of a), b) or c) is enriched in at least one NMR isotope, a method for identifying small molecules that bind to said isotopically labeled polypeptide involving NMR spectra;

---

2. claims: 2 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 13-16 and valine tRNA synthetase from S. pneumoniae;

---

3. claims: 3 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 22-25, b) an amino acid sequence having at least about 90% identity with the amino acid sequence set forth in SEQ ID NO: 23 or SEQ ID NO: 25, and aspartate tRNA synthetase from S. pneumoniae;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

4. claims: 4 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 31-34 and cysteine tRNA synthetase from H. pylori;

---

5. claims: 5 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 40-43 and malonyl-CoA-[acyl-carrier-protein] transacylase from P. aeruginosa;

---

6. claims: 6 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 49-52 and glutamate tRNA synthetase catalytic subunit from H. pylori;

---

7. claims: 7 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 58-61 and protein chain initiation factor IF-1 from P. aeruginosa;

---

8. claims: 8 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 67-70 and translation from H. pylori;

---

9. claims: 9 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 76-79 and threonine tRNA synthetase from S. pneumoniae;

---

10. claims: 10 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 85-88 and conserved hypothetical protein from H. pylori;

---

11. claims: 11 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 94-97 and cysteine tRNA synthetase from E. coli;

---

12. claims: 12 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 103-106 and DNA polymerase III, beta-subunit from H. pylori;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

13. claims: 13 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 112-115 and 3-oxoacyl-[acyl-carrier-protein] synthase II from S. pneumoniae;

---

14. claims: 14 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 121-124 and methionine aminopeptidase from H. pylori;

---

15. claims: 15 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 130-133 and pyruvate kinase from S. pneumoniae;

---

16. claims: 16 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 139-142 and threonine tRNA synthetase from H. pylori;

---

17. claims: 17 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 148-151 and putative ATP-binding component of a transport system from P. aeruginosa;

---

18. claims: 18 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 157-160 and glucose-6-phosphate dehydrogenase from S. pneumoniae;

---

19. claims: 19 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 166-169 and alanyl-tRNA synthetase from S. pneumoniae;

---

20. claims: 20 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 175-178 and glutamate tRNA synthetase catalytic subunit from S. pneumoniae;

---

21. claims: 21 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 184-187 and isoleucine tRNA synthetase from S. pneumoniae;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

---

22. claims: 22 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 193-196 and RNA polymerase beta-prime chain from S. pneumoniae;

---

23. claims: 23 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 202-205 and RNA polymerase sigma-70 factor from S. pneumoniae;

---

24. claims: 24 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 211-214 and transketolase 1 isoenzyme from S. pneumoniae;

---

25. claims: 25 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 220-223 and tryptophan tRNA synthetase from P. aeruginosa;

---

26. claims: 26 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 229-232 and holo-(acyl-carrier protein) synthase from E. faecalis;

---

27. claims: 27 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 238-241 and glutamate racemase from E. faecalis;

---

28. claims: 28 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 247-250 and glutamate racemase from S. pneumoniae;

---

29. claims: 29 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 256-259 and aspartate tRNA synthetase C from S. pneumoniae C;

---

30. claims: 30 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 265-268 and gamma-glutamyl phosphate reductase from E. faecalis;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

31. claims: 31 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 274-277 and triosephosphate isomerase from E. faecalis;

---

32. claims: 32 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 283-286 and cysteine tRNA synthetase from S. pneumoniae;

---

33. claims: 33 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 292-295 and branched-chain alpha-keto acid dehydrogenase from P. aeruginosa;

---

34. claims: 34 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 301-304 and tetrahydrodipicolinate (THDP) N-succinyltransferase from E. faecalis;

---

35. claims: 35 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 310-313 and elongation factor P (EF-P) from P. aeruginosa;

---

36. claims: 36 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 319-322 and fructose-biphosphate aldolase from E. faecalis;

---

37. claims: 37 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 328-331 and isopentyl diphosphate isomerase from E. faecalis;

---

38. claims: 38 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 337-340 and glutamate dehydrogenase from E. faecalis;

---

39. claims: 39 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 346-349 and GroEL protein from S. pneumoniae;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

---

40. claims: 40 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 355-358 and ATP-binding component of molybdate transport system from S. aureus;

---

41. claims: 41 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 364-367 and DNA topoisomerase IV subunit A from P. aeruginosa;

---

42. claims: 42 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 373-376 and GTP cyclohydrolase II from S. pneumoniae;

---

43. claims: 43 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 382-385 and putative aspartate-semialdehyde dehydrogenase from E. faecalis;

---

44. claims: 44 (completely), 45-67 (all partially)

idem as subject 1, but limited to SEQ ID NOS: 391-394 and elongation factor P (EF-P) from H. pylori;

INTERNATIONAL SEARCH REPORT

nformation on patent family members

International Application No
P[redacted]CA 03/00786

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0170955 A	27-09-2001	AU 4934501 A	03-10-2001
		CA 2404260 A1	27-09-2001
		EP 1268774 A2	02-01-2003
		WO 0170955 A2	27-09-2001
		US 2002061569 A1	23-05-2002
WO 02094868 A	28-11-2002	CA 2440368 A1	28-11-2002
		EP 1373310 A2	02-01-2004
		WO 02094868 A2	28-11-2002
EP 1094070 A	25-04-2001	EP 1094070 A2	25-04-2001
		JP 2001169787 A	26-06-2001
		US 2003021802 A1	30-01-2003
		US 2003202983 A1	30-10-2003
		US 6605696 B1	12-08-2003